Sell Cynosure (NSDQ: CYNO) for a 27% gain.

By Linda McDonough • February 14, 2017

Subscribers of Growth Stock Strategist might still own Cynosure, a stock I recommended last September.

The stock is up 28% today due to a buy out by Hologic for $66 per share in cash. It is unlikely a competing bid will come along so I suggest subscribers sell on this news. Just yesterday fat-busting competitor Zeltiq was purchased by drug heavyweight Allergan for $6 billion. Looks like getting thin is fattening investors’ wallets.

Stock Talk

Comments Oldest First

Comments Guidelines

Robert K

02/14/17 ‐ 3:49pm ET February 14, 2017 at 3:49pm ET

Yes, indeed; still owned it. Thanks Linda!

Linda McDonough

02/15/17 ‐ 7:30am ET February 15, 2017 at 7:30am ET

Happy to hear it- congrats!

Add New Comments

You must be logged in to post to Stock Talk

About The Author

Linda McDonough

Bio | Archive

Linda McDonough is a veteran hedge fund analyst who loves to break down company financial statements and identify market inefficiencies to uncover big opportunities. She believes in a boots-on-the-ground approach that includes surveying customers, interviewing company executives, or doing whatever it takes to see what others don't.

She's now brought her experience as a hedge fund analyst to subscribers of her Profit Catalyst Alert service. Her system identifies small- and mid-cap stocks that are about to move due to catalytic events that few others can identify...until it's too late. These events often times result in massive gains for her followers.